All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.